The second generation G-Rex500M-CS improves on the materials and ergonomics of the original G-Rex while retaining the same cell expansion performance.
St. Paul, MN, November 10, 2021 – ScaleReady announced today the launch of a second-generation G-Rex®500M-CS product that is designed to move cell and gene therapy manufacturing to a greater state of practicality and simplicity.
ScaleReady is a joint venture founded by Fresenius Kabi, Bio-Techne (NASDAQ: TECH), and Wilson Wolf.
“As cell and gene therapies continue to show great lifesaving potential, the need for reliable and automatable closed system cell expansion has never been more important,” said Josh Ludwig, Global Director of Commercial Operations, ScaleReady. “The second-generation G-Rex helps advance our mission to provide the cell and gene therapy industry with the most scalable, cost-effective and practical manufacturing platform.”
The second-generation G-Rex500M-CS is Wilson Wolf’s most comprehensive device for large-scale therapeutic cell expansion. It integrates several attributes to ensure consistently reliable generation of high-quality cells including:
• Shelf-life extension to three years
• Wider range of operating options
• Improved ergonomics
• Supply chain safety enhancements
• A certificate of compliance that anticipates future regulatory requirements
“G-Rex® bioreactors are the only cell expansion technology in which cells can receive virtually unlimited oxygen and nutrients on demand. This is the key to exceptional repeatability and high cell quality, and it sets the stage for simple and practical automation,” said John Wilson, Chief Executive Officer, Wilson Wolf. “Through ScaleReady, and its network of customers and likeminded vendors, we are working to automate cell and gene therapy manufacturing so that cost-effective and potentially life-saving therapies can reach a wide segment of society.”
# # #
ScaleReady is bringing the future of cell and gene therapies to life with its powerful and versatile manufacturing platform. ScaleReady delivers rapid expansion of immune cells at any scale—reducing complexity and cost, while providing superior repeatability and cell quality. Founded in 2020, ScaleReady is a joint venture of Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together tools and technologies for cell culture, cell activation, gene editing and cell processing from each founding partner. Learn more at www.scaleready.com.
About Wilson Wolf
Based in St. Paul, Minnesota, Wilson Wolf (www.wilsonwolf.com) was founded in 1998 to pioneer the development of innovative cell culture technologies and has created patented products and protocols for numerous applications including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. Over the last 5 years, its G-Rex® product line has experienced an average annual sales growth rate of 50% and is commonly used in every phase of cell and gene therapy manufacturing.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.
MEDIA AND INVESTOR CONTACTS
Katy O’Neill, P +1 651-789-2248 | C +1 862-219-0105
John Wilson, +1 651-628-9259
David Clair, +1 612-730-6463
Matt Kuhn 1-847-220-3033